丽珠医药(01513.HK)莱康奇塔单抗注射液上市许可申请获国家药监局受理

Group 1 - The core point of the article is that Lizhu Pharmaceutical (01513.HK) announced that its subsidiary, Lizhu Biopharmaceutical, has received a "Notice of Acceptance" from the National Medical Products Administration for the registration application of the monoclonal antibody injection, Laikangqita, developed in collaboration with Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd. [1] - The intended indication for Laikangqita is for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy [1]